Novavax Inc (NVAX)
4.93
+0.22
(+4.67%)
USD |
NASDAQ |
May 03, 16:00
4.90
-0.03
(-0.61%)
After-Hours: 20:00
Novavax Enterprise Value: 289.48M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 289.48M |
| May 02, 2024 | 258.69M |
| May 01, 2024 | 253.09M |
| April 30, 2024 | 205.51M |
| April 29, 2024 | 199.91M |
| April 26, 2024 | 171.92M |
| April 25, 2024 | 152.33M |
| April 24, 2024 | 180.32M |
| April 23, 2024 | 185.91M |
| April 22, 2024 | 169.12M |
| April 19, 2024 | 155.12M |
| April 18, 2024 | 143.93M |
| April 17, 2024 | 143.93M |
| April 16, 2024 | 157.92M |
| April 15, 2024 | 176.12M |
| April 12, 2024 | 198.51M |
| April 11, 2024 | 201.31M |
| April 10, 2024 | 195.71M |
| April 09, 2024 | 218.10M |
| April 08, 2024 | 219.50M |
| April 05, 2024 | 218.10M |
| April 04, 2024 | 220.90M |
| April 03, 2024 | 234.90M |
| April 02, 2024 | 233.50M |
| April 01, 2024 | 250.29M |
| Date | Value |
|---|---|
| March 28, 2024 | 268.49M |
| March 27, 2024 | 278.28M |
| March 26, 2024 | 258.69M |
| March 25, 2024 | 272.69M |
| March 22, 2024 | 257.29M |
| March 21, 2024 | 260.09M |
| March 20, 2024 | 275.48M |
| March 19, 2024 | 290.88M |
| March 18, 2024 | 318.87M |
| March 15, 2024 | 339.86M |
| March 14, 2024 | 296.48M |
| March 13, 2024 | 334.26M |
| March 12, 2024 | 307.67M |
| March 11, 2024 | 317.47M |
| March 08, 2024 | 362.26M |
| March 07, 2024 | 384.65M |
| March 06, 2024 | 384.65M |
| March 05, 2024 | 379.05M |
| March 04, 2024 | 367.85M |
| March 01, 2024 | 353.86M |
| February 29, 2024 | 290.88M |
| February 28, 2024 | 216.70M |
| February 27, 2024 | 442.03M |
| February 26, 2024 | 369.25M |
| February 23, 2024 | 339.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-349.18M
Minimum
Mar 23 2023
22.60B
Maximum
Feb 08 2021
4.098B
Average
847.25M
Median
Mar 25 2020
Enterprise Value Benchmarks
| Pfizer Inc | 215.90B |
| Moderna Inc | 39.38B |
| Agilent Technologies Inc | 41.67B |
| Halozyme Therapeutics Inc | 6.225B |
| Vaxart Inc | 87.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -178.39M |
| Revenue (Quarterly) | 253.40M |
| Total Expenses (Quarterly) | 436.97M |
| EPS Diluted (Quarterly) | -1.47 |
| Gross Profit Margin (Quarterly) | 38.84% |
| Profit Margin (Quarterly) | -70.40% |
| Earnings Yield | -112.8% |
| Normalized Earnings Yield | -112.78 |